No correlation between MTHFR c.677 C > T, MTHFR c.1298 A > C, and ABCB1 c.3435 C > T polymorphisms and methotrexate therapeutic outcome of rheumatoid arthritis in West Algerian population

Abstract

We have demonstrated, for the first time in the West Algerian population, that these polymorphisms were not predictive for clinical response and/or ADRs to MTX therapeutic outcome.

Membrane‐Spanning Protein Genetic Polymorphisms Related to Methotrexate Therapeutic Outcomes in a Chinese Rheumatoid Arthritis Population

“…34 In Spain, Sala-Icardo et al 35 predicted that the ABCB1 transporter could be useful for estimating the increased risk of MTX toxicity in patients. However, in a West Algerian study, 17 no relationship was found between ABCB1 and responders or ADRs, similar to our study. Our results indicate that genetic polymorphisms in ABCB1 (rs1045642) are not associated with the toxicity or efficacy of oral MTX in RA patients in China.…”

“…The disease activity score in 28 joints (DAS28), which is calculated on the basis of the erythrocyte sedimentation rate, was used to evaluate the MTX treatment response (calculated formula [0.56 × √(TJC28) +0.28 × √(SJC28) + 0.70 × ln (erythrocyte sedimentation rate)] 1.08 + 0.16) . The occurrence of MTX‐related toxicity, defined as patients presenting any ADRs related to MTX, was recorded upon each visit . The ADRs mainly included gastrointestinal reactions (abdominal and stomach pain, diarrhea, nausea, hepatic reactions, and indigestion or anorexia), respiratory reactions (interstitial lung disease), and general reactions (pain throughout the body, erythema of the extremities, hair loss, and vertigo reactions), according to other studies .…”

“…17 The ADRs mainly included gastrointestinal reactions (abdominal and stomach pain, diarrhea, nausea, hepatic reactions, and indigestion or anorexia), respiratory reactions (interstitial lung disease), and general reactions (pain throughout the body, erythema of the extremities, hair loss, and vertigo reactions), according to other studies. [17][18][19] Adverse drug events were observed after 3 months. The response of RA treated with MTX changed >0.6 in DAS28 before and after MTX treatment, in contrast to nonresponse.…”

Pharmacogenetics: A strategy for personalized medicine for autoimmune diseases

“…Unexpectedly, these results were disproved in subsequent studies, but new evidence of the association of MTX‐related adverse effects with MTHFR A1298C (rs1801131) polymorphism have been proposed . For example, no correlation was observed between MTHFR C677T (rs1801133) and MTHFR A1298C (rs1801131) polymorphism and MTX therapeutic outcomes for RA in a West Algerian population …”

“…[119][120][121] For example, no correlation was observed between MTHFR C677T (rs1801133) and MTHFR A1298C (rs1801131) polymorphism and MTX therapeutic outcomes for RA in a West Algerian population. 122 Except for association of recessive and codominant models of rs1801131 in a South Asian population, there has been no evidence for either of these 2 SNPs being related to the efficacy of MTX in RA according to various meta-analyses. [123][124][125][126] A recent meta-analysis has showed associations between the MTX response in RA patients for MTHFR A1298C, but not for MTHFR C677T (rs1801133).…”